Cary Vance serves as the Interim Chief Executive Officer of AVITA Medical Inc., a regenerative and aesthetic medicine company pioneering spray-on skin treatments like ReCell. With over 25 years of executive leadership in the medical device and biotechnology sectors, Vance joined AVITA in 2022 as Chief Operating Officer, bringing a wealth of experience from prior roles at industry leaders such as Integra LifeSciences, where he held senior positions in global operations and commercial strategy. His career also includes key contributions at companies like Convatec and Hollister, where he drove operational efficiencies and market expansions in wound care and advanced therapeutics. Vance's notable achievements include spearheading the successful commercialization of innovative wound management products, resulting in multi-million-dollar revenue growth and expanded market access across North America and Europe. At Integra LifeSciences, he led cross-functional teams to achieve FDA approvals and streamline supply chains, enhancing product delivery during critical periods. His strategic acumen has been recognized through industry awards and his involvement in advisory boards for medtech innovation. In his current role at AVITA Medical, Vance is guiding the company through a pivotal growth phase, focusing on accelerating ReCell adoption for burns, chronic wounds, and surgical applications while strengthening the commercial organization. Under his interim leadership, AVITA has advanced key clinical programs and partnerships, positioning the company for sustained profitability and global expansion in regenerative medicine.